Harpoon Therapeutics (NASDAQ: HARP) is one of 114 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare Harpoon Therapeutics to related businesses based on the strength of its analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.
This table compares Harpoon Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Harpoon Therapeutics Competitors||-5,144.22%||-64.24%||-27.96%|
Valuation & Earnings
This table compares Harpoon Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Harpoon Therapeutics||$4.75 million||N/A||-0.50|
|Harpoon Therapeutics Competitors||$897.63 million||$190.37 million||-1.33|
Harpoon Therapeutics’ competitors have higher revenue and earnings than Harpoon Therapeutics. Harpoon Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
47.9% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a summary of current ratings for Harpoon Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Harpoon Therapeutics Competitors||834||2774||6059||261||2.58|
Harpoon Therapeutics presently has a consensus price target of $23.50, suggesting a potential upside of 84.60%. As a group, “Biological products, except diagnostic” companies have a potential upside of 33.52%. Given Harpoon Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Harpoon Therapeutics is more favorable than its competitors.
Harpoon Therapeutics beats its competitors on 7 of the 11 factors compared.
Harpoon Therapeutics Company Profile
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. It is involved in developing HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; and HPN536 for the treatment of ovarian cancer and other mesothelin expressing tumors, as well as other products targeting tumor-associated antigens for the treatment of multiple myeloma and small-cell lung cancer. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.